Stockscreener 앱 받기
10.86
7.63%
0.77
시간 외 거래:
11.08
0.22
+2.03%
전일 마감가:
$10.09
열려 있는:
$9.985
하루 거래량:
1.89M
Relative Volume:
1.06
시가총액:
$964.09M
수익:
$71.64M
순이익/손실:
$-294.57M
주가수익비율:
-3.2437
EPS:
-3.348
순현금흐름:
$-84.46M
1주 성능:
+13.48%
1개월 성능:
-3.38%
6개월 성능:
+30.69%
1년 성능:
+64.55%
1일 변동 폭
$9.92
$11.02
1주일 범위
$9.46
$11.31
52주 변동 폭
$6.95
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
10.86 | 882.42M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes - Stock Titan
Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade - marketbeat.com
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology FY2029 EPS Cut by Brookline Capital Markets - marketbeat.com
Kura Oncology (KURA) Q2 2026 Earnings Call: KOMZIFTI-Umsatz erreicht 9,1 Mio. USD - TradingKey
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - moomoo.com
BofA Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside - TradingView
Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings - marketbeat.com
KURA Maintained by Wedbush -- Price Target Raised to $38 - GuruFocus
Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush - marketbeat.com
Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating - marketscreener.com
Kura Oncology (NASDAQ:KURA): What Does the Latest Update Mean for Clinical Evidence? - Kalkine Media
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $31.83, Implies 220% Upside - tradingview.com
Kura Oncology (KURA) Q2 2026 Results Highlight Valuation Challen - GuruFocus
Kura Oncology Q2 2026 Earnings Call Transcript - marketbeat.com
Kura Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Kura Oncology Q2 EPS $(0.77) beats estimate, sales miss - scanx.trade
Kura Oncology Q2 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains - Investing.com
Kura Oncology (NASDAQ:KURA) Issues Earnings Results - marketbeat.com
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Kura Oncology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology Inc (KURA) Reports Q2 Revenue of $20.9M with Net L - GuruFocus
Kura Oncology Q2 Diluted Loss Widens, Revenue Rises - marketscreener.com
Kura Oncology: Q2 Earnings Snapshot - ktvb.com
Earnings Flash (KURA) Kura Oncology Posts Q2 Loss Per Share $0.77, vs. FactSet Est of Loss $0.88 - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q2 2026 Earnings - Quiver Quantitative
Q2 2026 Kura Oncology, Inc. Earnings Call Transcript - GuruFocus
Kura Oncology (KURA) grows revenue to $39.1M but widens net loss - Stock Titan
Kura Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake - TradingView
Kura Oncology Reports Second Quarter 2026 Financial Results - The Manila Times
Earnings Flash (KURA) Kura Oncology, Inc. Reports Q2 Revenue $20.9M, vs. FactSet Est of $20.2M - marketscreener.com
BRIEF-Kura Oncology Q2 Operating Expenses USD 93.884 Million - TradingView
Kura Oncology, Inc. expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Eps Diluted (TTM) - Zacks Investment Research
Kura Oncology (KURA) Advances Menin Inhibitor Research Amid Mixed Market Signals - GuruFocus
Kura Oncology highlights ziftomenib preclinical activity, menin binding profile in Blood publication - Bitget
Kura Oncology publishes preclinical data on ziftomenib in Blood By Investing.com - Investing.com South Africa
Kura Oncology publishes preclinical data on ziftomenib in Blood - Investing.com
Kura Oncology publishes study highlighting zift... - Pluang
Kura Oncology Announces Blood Publication Detailing Discovery, Preclinical Characterization and Resistance Profile of Ziftomenib - Quiver Quantitative
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity - The Manila Times
Kura Oncology Announces Publication in Blood Highlighting - GlobeNewswire
Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA - marketbeat.com
Dimensional Fund Advisors LP Increases Holdings in Kura Oncology, Inc. $KURA - marketbeat.com
Sei Investments Co. Boosts Holdings in Kura Oncology, Inc. $KURA - marketbeat.com
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kura Oncology, Inc. (KURA) stock price, news, quote and history - Yahoo Finance Australia
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):